Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00103194 | Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2014 | clinicaltrials |
| NCT00477386 | Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | Indiana UniversityOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01451424 | Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids | completed | Phase 2 | 40 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00323882 | Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 28, 2014 | clinicaltrials |
| NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | completed | Phase 2 | 64 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Aug 6, 2014 | clinicaltrials |
| NCT00476645 | Fulvestrant in Hormone Refractory Prostate Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00672594 | Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy | completed | Phase 2 | 30 | Duke UniversityOTHER | 1 | Aug 4, 2014 | clinicaltrials |
| NCT00548418 | Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer | completed | Phase 2 | 27 | Washington University School of MedicineOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT01424930 | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 25 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00349557 | Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer | completed | Phase 2 | 18 | Benaroya Research InstituteOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00278993 | Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | completed | Phase 2 | 108 | Eisai Inc.INDUSTRY | 1 | Jul 14, 2014 | clinicaltrials |
| NCT00882258 | Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | completed | Phase 2 | 144 | Repros Therapeutics Inc.INDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00515073 | Papillary Serous Carcinoma of the Endometrium | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 3, 2014 | clinicaltrials |
| NCT00919035 | Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients | completed | Phase 2 | 21 | Oncology Specialists, S.C.OTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00459654 | A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer | completed | Phase 2 | 64 | BayerINDUSTRY | 2 | Jun 25, 2014 | clinicaltrials |
| NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 121 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2014 | clinicaltrials |
| NCT01163552 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | completed | Phase 2 | 5 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00390468 | Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00330161 | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00003449 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 35 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183924 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00083122 | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00093496 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT00176605 | Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer | completed | Phase 2 | 15 | Rutgers, The State University of New JerseyOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT01088529 | Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer | completed | Phase 2 | 66 | Cougar Biotechnology, Inc.INDUSTRY | 1 | May 15, 2014 | clinicaltrials |
| NCT00126542 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00170677 | Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer | completed | Phase 2 | 194 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 14, 2014 | clinicaltrials |
| NCT00087139 | Ixabepilone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00436644 | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | completed | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Apr 16, 2014 | clinicaltrials |
| NCT01631903 | Extension of Study ZPV-200 | completed | Phase 2 | 48 | Repros Therapeutics Inc.INDUSTRY | 1 | Apr 16, 2014 | clinicaltrials |
| NCT01739621 | Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 | completed | Phase 2 | 40 | Repros Therapeutics Inc.INDUSTRY | 0 | Apr 16, 2014 | clinicaltrials |
| NCT00072670 | A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | completed | Phase 2 | 59 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Apr 8, 2014 | clinicaltrials |
| NCT00414388 | Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Oncology Specialists, S.C.OTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT00487721 | The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer | completed | Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT00439270 | Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00654186 | Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients | completed | Phase 2 | 32 | Oncology Specialists, S.C.OTHER | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00101192 | Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | completed | Phase 2 | 76 | Gynecologic Oncology GroupNETWORK | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00859729 | Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Uppsala UniversityOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00770848 | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 162 | AmgenINDUSTRY | 0 | Mar 10, 2014 | clinicaltrials |
| NCT01338792 | Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer | completed | Phase 2 | 47 | University of Southern CaliforniaOTHER | 1 | Mar 10, 2014 | clinicaltrials |
| NCT00015977 | Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 13 | University of ChicagoOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00543049 | Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor | completed | Phase 2 | 73 | AGO Study GroupOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00258284 | Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 6, 2014 | clinicaltrials |
| NCT00078923 | Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate | completed | Phase 2 | 32 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 5, 2014 | clinicaltrials |
| NCT00086892 | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 5 | Feb 14, 2014 | clinicaltrials |
| NCT00087087 | Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Feb 14, 2014 | clinicaltrials |
| NCT00087100 | Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Feb 14, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2014source: clinicaltrials